{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:20:35Z","timestamp":1780456835177,"version":"3.54.1"},"reference-count":23,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,9,4]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease that affects approximately 30% of psoriasis patients. In most cases, skin disease clearly precedes the musculoskeletal disease. Some studies suggest that targeted treatment may intercept the disease course and prevent psoriasis patients from developing PsA. A recent population-based retrospective analysis in 15\u2009501 psoriasis patients evaluated the association between different biological treatment strategies and time to incident inflammatory arthritis based on data in a US electronic health records database. A cumulative incidence of 2.6 PsA cases per 100 person-years was determined. The multivariable regression analysis revealed a significantly lower risk of developing inflammatory arthritis in patients who had been prescribed interleukin (IL)-12\/23 or IL-23 inhibitors compared with tumour necrosis factor (TNF) inhibitor-treated patients, whereas there was no significant difference in risk for patients prescribed inhibitors of IL-17 versus TNF. Although the analysis was based on a large set of clinical data and the findings were rigorously evaluated, there are some limitations in interpretation due to the study design. Prospective clinical trials are missing, and retrospective data analyses from clinical trials or population-based studies show conflicting results. Overall, the recent data on prevention of PsA in patients with psoriasis support the high need to characterise biomarkers of increased risk and perform prospective clinical trials to give a clear guidance on possibilities for disease interception in psoriatic disease.<\/jats:p>","DOI":"10.1136\/rmdopen-2023-003166","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:35:56Z","timestamp":1695299756000},"page":"e003166","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3579-5574","authenticated-orcid":false,"given":"Michaela","family":"Koehm","sequence":"first","affiliation":[{"name":"Division of Translational Rheumatology, Immunology, Inflammation Medicine, Goethe University Frankfurt, Frankfurt am Main, Hessen, Germany"},{"name":"Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany"},{"name":"Clinical Research, Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[{"name":"Division of Translational Rheumatology, Immunology, Inflammation Medicine, Goethe University Frankfurt, Frankfurt am Main, Hessen, Germany"},{"name":"Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany"},{"name":"Clinical Research, Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"2025090312561316000_9.3.e003166.1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64 Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025090312561316000_9.3.e003166.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0"},{"key":"2025090312561316000_9.3.e003166.3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312561316000_9.3.e003166.4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"2025090312561316000_9.3.e003166.5","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatology"},{"key":"2025090312561316000_9.3.e003166.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221255"},{"key":"2025090312561316000_9.3.e003166.7","first-page":"S12","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","volume":"20 Suppl 1","author":"Fragoulis","year":"2022","journal-title":"Musculoskeletal Care"},{"key":"2025090312561316000_9.3.e003166.8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with Guselkumab vs. Secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2025090312561316000_9.3.e003166.9","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40744-021-00378-w","article-title":"Predictors, risk factors, and incidence rates of Psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis","volume":"8","author":"Zabotti","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025090312561316000_9.3.e003166.10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","article-title":"Dactylitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312561316000_9.3.e003166.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02530-x","article-title":"Biomechanical stress in the context of competitive sports training triggers Enthesitis","volume":"23","author":"Simon","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090312561316000_9.3.e003166.12","doi-asserted-by":"crossref","DOI":"10.3390\/medicina58111557","article-title":"Ultrasound enthesitis in psoriasis patients with or without psoriatic arthritis, a cross-sectional analysis","volume":"58","author":"Agache","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"2025090312561316000_9.3.e003166.13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001067","article-title":"Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia","volume":"5","author":"Zabotti","year":"2019","journal-title":"RMD Open"},{"key":"2025090312561316000_9.3.e003166.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in preventing arthritis in a multicentre psoriasis at-risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"},{"key":"2025090312561316000_9.3.e003166.15","doi-asserted-by":"crossref","unstructured":"Aronovich A , Novikov I , Pavlovsky L . Do biologic treatments for psoriasis lower the risk of psoriatic arthritis. Am J Clin Dermatol June 21, 2023. doi:10.1007\/s40257-023-00801-8","DOI":"10.1007\/s40257-023-00801-8"},{"key":"2025090312561316000_9.3.e003166.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220761"},{"key":"2025090312561316000_9.3.e003166.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219961"},{"key":"2025090312561316000_9.3.e003166.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220865"},{"key":"2025090312561316000_9.3.e003166.19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090312561316000_9.3.e003166.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224148"},{"key":"2025090312561316000_9.3.e003166.21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-021-00650-5","article-title":"Arthritis interception in patients with psoriasis treated with guselkumab","volume":"12","author":"Zabotti","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025090312561316000_9.3.e003166.22","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102387","article-title":"Omics and multi-Omics analysis for the early identification and improved outcome of patients with psoriatic arthritis","volume":"10","author":"Gurke","year":"2022","journal-title":"Biomedicines"},{"key":"2025090312561316000_9.3.e003166.23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00468","article-title":"Innovative imaging technique for visualization of vascularization and established methods for detection of musculoskeletal inflammation in psoriasis patients","volume":"7","author":"K\u00f6hm","year":"2020","journal-title":"Front Med (Lausanne)"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:56:19Z","timestamp":1756929379000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,21]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/rmdopen-2023-003166"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003166","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}